Publications by authors named "Laura Saint-Lary"
In 2018, a significant neural tube defects (NTD) signal was reported after pre-conceptional exposure to dolutegravir, but was not confirmed in further analysis. Since 2019, dolutegravir-based regimen, an integrase inhibitor (INI), is recommended by WHO as the most-effective first-line therapy in all patients living with HIV. To explore the potential INI-related teratogenic effect, we searched disproportionate signals between exposure to INI-class drugs and congenital anomalies, compared to non-INI drugs, using the international pharmacovigilance database, VigiBase®.
View Article and Find Full Text PDFBackground: About 1.3 million pregnant women lived with HIV and were eligible to receive antiretroviral therapy (ART) worldwide in 2021. The World Health Organization recommends protease inhibitors (PI)-based regimen as second or third-line during pregnancy.
View Article and Find Full Text PDFArticle Synopsis
- Abacavir, a nucleoside reverse transcriptase inhibitor, is evaluated for its safety and efficacy in treating HIV in children and adolescents to guide WHO's 2021 pediatric ART recommendations.
- A systematic review of studies published from 2009 to 2022 involved various age groups, assessing both safety (e.g., adverse events) and efficacy (e.g., viral load and CD4 counts) of abacavir-based therapies.
- Out of 1777 records, only 33 studies met the eligibility criteria for inclusion, indicating a rigorous selection process for relevant data.
Article Synopsis
- Atazanavir/ritonavir is recommended as a second-line HIV treatment for children over 3 months old, and a systematic review was conducted to assess its safety and effectiveness in this population.
- Researchers analyzed data from 1,085 records, ultimately including five studies with 975 participants, finding a 19% treatment discontinuation rate and reporting transient hyperbilirubinemia as the main adverse effect.
- The treatment led to improved immune response (increased CD4 counts) and reduced HIV viral load, but more research is needed to fully understand its safety and effectiveness for children and adolescents.
Aims: In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system.
View Article and Find Full Text PDFThe consistency of cerebrospinal fluid amyloid-β (Aβ)42/40 ratio and Aβ42 has not been assessed in the AT(N) classification system. We analyzed the classification changes of the dichotomized amyloid status (A+/A-) in 363 patients tested for Alzheimer's disease biomarkers after Aβ42 was superseded by the Aβ42/40 ratio. The consistency of Aβ42 and the Aβ42/40 ratio was very low.
View Article and Find Full Text PDF